# Turinabol

*Also known as: 4-Chlorodehydromethyltestosterone, Tbol*

Oral cross between Dbol and Clostebol; low water retention, moderate liver toxicity. Peak calibrated.

## Overview

Turinabol (4-chlorodehydromethyltestosterone, or Tbol) is an oral anabolic-androgenic steroid developed in the 1960s, structurally a hybrid of metandienone and clostebol. The 4-chloro modification blocks aromatization, so it does not convert to estrogen, and the 17-alpha-methyl group lets it survive oral first-pass metabolism. It binds the androgen receptor and drives protein synthesis with relatively low water retention compared with metandienone. The dataset lists a half-life of about 16 hours, with 100% nominal bioavailability. Research and athletic protocols that documented its use typically split dosing twice daily given that moderate half-life. It carries moderate hepatotoxicity from the 17-alpha-alkyl group, so liver enzymes warrant monitoring. Long-lived nor-metabolites stay detectable for 4 to 6 weeks after a single exposure.

## Pharmacokinetics

- **Model tier:** simple
- **Half-life:** 0.7 days (16.000008 hours)
- **Cmax:** 49.9 ng/dL
- **Bioavailability:** 100%

## Dosing

- **Default dose:** 30 mg
- **Typical range:** 20–60 mg
- **Units:** ng/dL

## Harm reduction

- **Aromatizes:** No
- **DHT derivative:** No
- **Hepatotoxicity:** moderate
- **Injection frequency:** Oral, 2×/day

## Detection time (anti-doping)

- **Window:** 28–42 days post-last-dose
- **Target metabolite:** 4-chloro-18-nor-17β-hydroxymethyl-androst-13-en-17α-ol
- **Assay:** LC-MS/MS
- **Notes:** Long-lived nor-metabolite (20βOH-NorDHCMT). 60-day excretion study confirms multi-week detection.

## Source

- **Label:** PubMed / Bionity
- **URL:** https://pubmed.ncbi.nlm.nih.gov/1798729/
- **Notes:** Cmax calibrated to ng/dL serum peak.

---

**Canonical URL:** https://anabolicdex.com/compounds/turinabol
**Plot:** https://anabolicdex.com/plot?compound=turinabol